Related by context. All words. (Click for frequent words.) 69 Pharma Merck Serono 68 R sorafenib tablets 68 Initiates Enrollment 68 evaluating picoplatin 68 5 FU leucovorin 68 Completes Patient Enrollment 67 R lenalidomide 67 pralatrexate injection folate analogue 67 FOLFOX6 chemotherapy regimen 67 Xeloda ® 67 trastuzumab Herceptin R 67 INSPIRE Trial Phase III 66 docetaxel Taxotere R 66 sanofi aventis Bayer Schering 66 Initiates Clinical Trial 66 Submits Biologics License Application 66 dasatinib Sprycel ® 66 CYT# potent vascular disrupting 66 LymphoStat B belimumab 65 monoclonal antibody IgG1 Mab 65 topical gel formulation 65 Telik logo TELINTRA 65 PRN FDA Approves 65 virus HCV protease inhibitor 65 Pegloticase 65 Combination REOLYSIN R 65 MAGE A3 ASCI 65 Meets Primary Endpoint 65 IG HCR ;) CO 65 OMP #R# 65 Peginterferon alfa 2b 65 XL# anticancer compounds 65 evaluating tivozanib 65 interferon beta 1a infertility 65 topical antifungal product 65 lintuzumab SGN 65 Ostarine ™ 65 refractory chronic lymphocytic 65 Genentech Wyeth Pharmaceuticals 65 nilotinib Tasigna ® 65 Dementia Related Psychosis 65 Pruvel TM 65 R Saizen R 65 Crofelemer budesonide foam 65 orally administered inhibitor 65 delivers fluocinolone acetonide FA 65 Aflibercept 65 irinotecan doxorubicin oxaliplatin paclitaxel 65 Merck OSI Pharmaceuticals 64 peptidic compound 64 Initiates Phase III 64 Hsp# Inhibitor 64 Xcytrin R 64 Refractory Hodgkin Lymphoma 64 markets Testim ® 64 Budesonide foam crofelemer 64 IgG1 monoclonal antibody 64 VEGFR2 inhibitor 64 reduce serum phosphate 64 novel tubulin binding 64 pharmacogenomic translational research 64 ® lenalidomide 64 metaglidasen 64 Patients Treated With 64 novel antimitotic agent 64 Receives Fast Track 64 Presents Positive 64 dihydrochloride Tablets 64 ENL recurrence 64 mitogen activated ERK kinase 64 novel emulsion formulation 64 sapacitabine CYC# 64 Oral Calcitonin 64 Initiates Phase II 64 Mg Usa 64 Panzem R NCD 64 IMiDs ® 64 Announces Tentative Approval 63 MKC# MT 63 Inc. www.micromet inc.com 63 ® bortezomib 63 developing Bicifadine serotonin 63 compound INCB# 63 promotes MERREM ® 63 Perifosine KRX 63 sorafenib tablets 63 Hormone Refractory Prostate Cancer 63 Files IND 63 recurrent metastatic ovarian cancer 63 Novel Oral 63 carcinoma mCRC 63 RANK Ligand inhibitor 63 Licenses Novel 63 Submits Response 63 investigational humanized monoclonal antibody 63 Phase 2b Clinical Trial 63 oral ridaforolimus 63 EOquin TM phase 63 elotuzumab 63 vapreotide acetate 63 Romidepsin 63 SPRYCEL ® 63 Submits NDA 63 ZOLINZA 63 Trastuzumab DM1 63 Begins Dosing 63 triggers apoptosis programmed 63 Vidaza ® 63 Initiate Phase III 63 CYP#A# substrate 63 Vytorin combines 63 essential thrombocythemia ET 63 Randomized Phase II 63 Receives Orphan Drug Designation 63 candidates Azedra TM 63 platform HDL Mimetic 63 JAK2 Inhibitor 63 aflibercept VEGF Trap 63 M# rationally 63 BCG refractory carcinoma 63 Presents Preclinical Data 63 5 fluorouracil leucovorin 63 Adjuvant Treatment 63 markets HP Acthar 63 inflammatory PDE 63 mitoxantrone plus 63 Vitrasert R 63 Initiate Phase 63 LymphoStat B TM 63 Merck Serono Nycomed 62 R MSCRAMM 62 memantine HCl 62 gastrointestinal mucositis 62 TRIOLEX HE# APOPTONE HE# 62 myelodysplastic myeloproliferative diseases 62 unique alkylating agent 62 Namenda Memantine HCl 62 Metastatic Melanoma 62 Achieves Primary Endpoint 62 Previously Treated 62 Phase #b/#a clinical 62 Peginterferon Alfa 2a 62 interferon gamma 1b 62 Enrolls First 62 Wafer polifeprosan 62 Ovitrelle R Serostim 62 Biogen Genentech 62 AN# topical anti 62 IMiDs ® compound 62 Dose Escalation 62 dyslipidemia hypertension diabetes 62 including eniluracil ADH 62 Provectus Pharmaceuticals specializes 62 evaluating intravenous picoplatin 62 Obatoclax 62 Granted Orphan Drug 62 paclitaxel Taxol R 62 SUTENT ® 62 AAG geldanamycin analog 62 dependent kinase inhibitor 62 class mGluR5 inhibitor 62 CYP#A# CYP#D# 62 humanized therapeutic 62 TELINTRA R 62 evaluating satraplatin 62 Pruvel ™ prulifloxacin 62 please visit www.abraxane.com 62 folinic acid FA 62 Folfox 62 Receives Approvable Letter 62 metastatic colorectal carcinoma 62 small molecule glucokinase 62 sapropterin dihydrochloride 62 induced oral mucositis 62 Aeolus Pharmaceuticals Announces 62 Brentuximab Vedotin SGN 62 SinuNase ™ 62 PF # [002] 62 3 registrational trial 62 agonistic human 62 psoriasis inflammatory bowel 62 NU# direct 62 pentadentate logo R 62 Fovea Pharmaceuticals subsidiary 62 Hematology Molecular Pathology 62 Known hypersensitivity 62 IMPDH inhibitor 62 alvespimycin 62 erlotinib Tarceva ® 62 bone marrow reticulin deposition 62 PDX pralatrexate 62 relapsed MM 62 non porcine pancreatic 62 COPEGUS R 62 R roscovitine CDK cyclin 62 metastatic pancreatic 62 CG# oncolytic virus 62 dimebon latrepirdine 62 CysDisplay R 62 novel synthetic PEGylated 62 Cetuximab Erbitux 62 metformin sulfonylureas 62 Antibody Drug Conjugate 62 Cephalon GlaxoSmithKline 62 particularly SANCTURA XR 62 Trial Evaluating 62 Zemiva TM 62 Launches Generic Version 62 R metformin Concor 62 6 sulfatase 62 Cutaneous T 62 sunitinib Sutent ® 62 stage antibody MT# 62 CDK cyclin dependent 62 hypoxia activated prodrug 61 D aspartate NMDA receptor 61 markets COLAZAL 61 receiving INTRON 61 Annamycin 61 TRANSDUR ® 61 product candidate Lpathomab 61 ovarian esophageal 61 Second Pivotal Phase 61 IMiDs R 61 HGS ETR2 61 Through Glycoscience R 61 developing Zerenex TM 61 Syncria R 61 Receive Milestone Payment 61 Antigen Specific 61 Glufosfamide 61 TNFerade ™ 61 FDA Accepts 61 human IgG1 monoclonal 61 metastatic colorectal 61 HER2 Positive 61 brand ciclesonide HFA 61 Amigal TM 61 Initiates Phase 2b 61 modified glutathione analog 61 developing adecatumumab 61 TO AVOID PREGNANCY WHILE 61 BioSante Pharmaceuticals Announces 61 oral dihydropyrimidine dehydrogenase DPD 61 Boehringer Ingelheim MedImmune 61 Phase IIb Trial 61 ADP receptor antagonist 61 chronic eosinophilic leukemia 61 non nucleoside inhibitor 61 influenza BCX# purine nucleoside 61 PI3K/Akt pathway inhibitor 61 SPL# Gel vaginal microbicide 61 mapatumumab 61 Xenografts 61 cladribine Cladribine Tablets 61 hyperphenylalaninemia HPA due 61 evaluating T DM1 61 recombinant PSMA vaccine 61 systemic anaplastic large 61 Panzem R 61 oral picoplatin 61 Demonstrates Positive 61 evaluating Actimmune 61 Tibotec Therapeutics division 61 Belimumab 61 Nasdaq AEGR 61 acetonide FA 61 oral nucleoside analogue 61 Dyax logo 61 ALN PCS 61 HGS ETR1 mapatumumab 61 pipeline ImmunoGen collaborators 61 Presents Preclinical 61 novel VDA molecule 61 Efficacy Results 61 Septin9 biomarker 61 Plicera TM 61 R rilonacept Injection 61 highly purified pasteurized 61 albiglutide 61 commercialize SGN 61 targeted radiotherapeutic 61 NS5B polymerase 61 receiving chemoradiation therapy 61 Initiates Phase 61 Therapeutic Competitors Companies 61 plus prednisone 61 Completes Enrollment 61 Personalized Immunotherapy 61 Zalypsis 61 Genentech sanofi aventis 61 resistant hormone refractory 61 4SC AG ISIN DE# 61 known dihydropyrimidine dehydrogenase 61 Regeneron Pharma 61 R memantine HCl 61 GATTEX TM 61 telomerase therapeutic 61 Antitumor Activity 61 Other ImmunoGen collaborative 61 targeted anticancer biopharmaceuticals 61 advanced metastatic renal 61 stage IIIb IV 61 CYP#A# isoenzyme 61 antibiotic candidate Ramoplanin 61 COLAZAL R 61 developing Zerenex ferric 61 neuropathic pain metabolic diseases 61 manufactures minimally invasive 61 albiglutide currently 61 GVAX ® 61 Safinamide 61 irinotecan cisplatin 61 Degarelix 61 Ridaforolimus 61 ERBITUX cetuximab 61 candidate AQ4N 61 palonosetron hydrochloride Injection Dacogen 61 cyclophosphamide methotrexate 61 Alvine Pharmaceuticals 61 Matrix Phase 2b 61 treat refractory angina 61 factor TNF receptor 61 oral deforolimus 60 Inc Therapeutic Competitors 60 anti VEGF aptamer 60 Improves Survival 60 CLARITY study 60 Onyx Pharmaceuticals Announces 60 Patient Enrollment 60 hypereosinophilic syndrome 60 First Patient Enrolled 60 Suppository Hydrocortisone Acetate Rectal 60 induced mucositis 60 sapropterin dihydrochloride Tablets 60 Inc. Nasdaq IMGN 60 Kit CD# positive 60 novel orally inhaled 60 Paris IPN Euronext 60 ALN VSP Phase 60 Femring ® 60 * olmesartan medoxomil 60 Mylan Receives Approval 60 intravesical infusion therapy 60 TM Aganocide 60 certain protein tyrosine 60 Daclizumab 60 Naglazyme R 60 PROVENGE ® 60 methylnaltrexone bromide 60 TTF Therapy 60 PEGINTRON TM 60 pan histone deacetylase 60 acute peptic ulcer 60 PSMA ADC 60 dextromethorphan quinidine 60 Tyrosine Kinase Inhibitor 60 MEK Inhibitor 60 alfa 2a 60 Investigational Oral 60 metastatic malignant 60 estrogen receptor beta agonist 60 selective modulator 60 forodesine 60 Amgen Neulasta R 60 Clolar ® 60 Alfacell proprietary ribonuclease 60 huC# DM4 60 Zenvia ™ 60 Presents Positive Preclinical 60 MKC# 60 oral prodrug 60 Serostim ® 60 octreotide implant 60 TRACON Pharmaceuticals 60 castration resistant hormone refractory 60 non splenectomized 60 Acute Exacerbations 60 Submits Supplemental 60 Gentamicin Surgical Implant 60 secretory phospholipase A2 60 ATRA IV 60 Paclitaxel Carboplatin 60 sanofi aventis GlaxoSmithKline 60 SIX BSLN 60 de novo kidney transplant 60 Shows Efficacy 60 Investigational Treatment 60 Solazed TM 60 HuMax EGFr 60 adenosine injection 60 approved incretin mimetic 60 Tiuxetan 60 PNP inhibitor 60 Prolongs Survival 60 demonstrated antitumor activity 60 Commences Phase 60 phase III isavuconazole 60 oncolytic virus therapies 60 receptor tyrosine kinase inhibitor 60 sarcoma melanoma 60 NSABP C 60 Pivotal Phase III 60 Darinaparsin 60 Oral Fingolimod 60 squamous non 60 Receives Milestone Payment 60 oropharyngeal candidiasis OPC 60 solid tumors ZYBRESTAT 60 plasma kallikrein inhibitor 60 NCCN Updates 60 Aloprim TM allopurinol sodium 60 Inc. www.coopersurgical.com develops 60 Diffuse Large B 60 Sapacitabine 60 Pivotal Phase 60 cisplatin gemcitabine 60 oral Janus kinase 60 Aradigm Logo 60 Empatic ™ 60 Hedgehog Pathway Inhibitor 60 TNF Tumor Necrosis Factor 60 Pruvel ™ 60 Colaris Colaris AP 60 Severe Sepsis 60 receptor inhibiting monoclonal 60 Clinical Trial Results 60 Omacetaxine 60 R ferumoxytol Injection 60 Teva Provides Update 60 ThermoDox R 60 Humanized Anti 60 Complicated Skin 60 developing ostarine selective 60 5 HT2A inverse 60 IL# PE#QQR 60 evaluating mipomersen 60 DepoCyt ® Abelcet ® 60 EGFr humanized monoclonal antibody 60 humanized interleukin 6 60 rilonacept Injection 60 HCD# [002] 60 metastatic castration resistant 60 Successfully Completes Phase 60 PEGylated Fab fragment 60 evaluating satraplatin plus 60 Cardium Therapeutics TM 60 follicular Non Hodgkin 60 YOUR LOCAL ANIMAL SHELTER 60 lead molecular radiotherapeutic 60 Bullish Technical Alert 60 myocardial infarction ventricular fibrillation 60 investigational oral inhibitor 60 commercializing Loramyc ® 60 non constipating irritable 60 arsenic trioxide injection 60 Anti Tumor 60 Advanced Melanoma 60 Syndax Pharmaceuticals Inc. 60 Receives Orphan Drug 60 occlusion PAO 60 Long Term Efficacy 60 erlotinib Tarceva R 60 monoclonal antibody conjugated 60 cyclophosphamide doxorubicin vincristine 60 specific lectin receptors 60 € žÂ ¢ ÃÆ'à 60 somatropin Kuvan R 60 Cannabinor 60 atrial fibrillation budiodarone ATI 60 CEL SCI Phase III 60 Bayer HealthCare Onyx Pharmaceuticals 60 liposomal formulation 60 Vascular Disrupting Agent 59 active AKT inhibitor 59 Treatment Naive Patients 59 Initiates Clinical 59 inhibits dihydrofolate reductase 59 Anthracycline 59 ONYX PHARMACEUTICALS 59 Albuferon TM 59 candidate Hematide TM 59 Inc. Nasdaq OXGN 59 evaluating Xcytrin 59 Submits IND 59 PEGylated interferon beta 1a 59 indolent follicular non 59 Randomized Phase 59 Coadministration 59 FEMALES SHOULD BE ADVISED 59 leading oral taxane 59 Kuvan R 59 taxane chemotherapy administered 59 Initiates Dosing 59 PEGylated docetaxel 59 successfully commercialize Iluvien 59 Pemetrexed 59 Cloretazine ® 59 PROSTVAC ® 59 Anti Tumor Activity 59 molecular imaging radiopharmaceutical 59 Chronic Hepatitis C 59 metastatic ocular 59 % pramoxine HCl 59 multi kinase inhibitor 59 Telik Announces 59 Immunotherapeutic 59 Phase III Trial 59 Staphylococcus aureus Immune Globulin 59 ospemifene 59 TM pralatrexate injection 59 FOLOTYN ® 59 FDA APPROVES 59 angiotensin analog 59 Epratuzumab 59 humanized anti 59 ADVANCE ILLUMINATE 59 CD# CEA 59 Relapsed Multiple Myeloma 59 dasatinib Sprycel 59 Intravitreal 59 Phase IIb Clinical Trial 59 R bisoprolol Euthyrox 59 Prednisone Against Refractory 59 NASDAQ MNKD focuses 59 investigational monoclonal antibody 59 GlaxoSmithKline Genentech 59 Dacetuzumab 59 toenail onychomycosis 59 phosphorylase PNP inhibitor 59 Kinase Inhibitor 59 label Lipofen R 59 aerosolized AAT 59 NYSE Amex PTN 59 cytidine nucleoside analog 59 Ribavirin causes 59 metabolic disorders Saizen R 59 hypertrichosis occurred 59 sulfonylhydrazine class 59 kidney urologic 59 therapeutically inactive prodrug 59 candidate deforolimus 59 UCB www.ucb group.com 59 SABER ™ 59 acyclovir Lauriad R 59 EXPLORE Xa 59 MSCRAMM ® 59 cell carcinoma RCC 59 Single Dose 59 DG# compounds targeting 59 Deforolimus 59 TRX1 59 data management Clintrial 59 phenylketonuria PKU developed 59 DIFICID ™ 59 mecarbil 59 R bortezomib 59 Phase 2a Trial 59 Atripla combines 59 Bezielle 59 ISTODAX ® 59 SIX RO ROG 59 Vicinium TM 59 Takeda Kyowa Hakko Kirin 59 Dose Ranging Study 59 website http:/www.depomed.com 59 Randomized Double blind 59 CINQUIL 59 Asentar TM 59 Dapagliflozin 59 accumulate preferentially 59 Germany FSE SCH 59 Bristol Myers Squibb Celgene 59 Previously Untreated 59 candidate XP# 59 metastatic renal 59 LHRH receptor positive 59 Newly Diagnosed Multiple Myeloma 59 XP# XP# 59 include ClindaReach TM 59 Aflibercept VEGF Trap 59 CCR9 antagonist 59 keloid scarring 59 CTA# Injection 59 MCSP respectively 59 HGS ETR1 59 Epothilone D 59 Phase 1b clinical trials 59 RON Notch 59 Files Investigational 59 cancer neuroendocrine tumor 59 5 HT4 59 Refractory Angina 59 delta gamma agonist 59 generation purine nucleoside 59 forodesine purine nucleoside phosphorylase 59 Renal Cell Carcinoma 59 telomerase inhibitor drug 59 endoscopic autofluorescence imaging 59 mild vasodilator 59 PHX# 59 vitreoretinal disorders 59 metastatic GIST 59 cardiac myosin activator omecamtiv 59 pulmonology portfolio 59 include Healive TM 59 Vicriviroc 58 includes Dideco CarboMedics 58 Improves Outcomes 58 NEBIDO VANTAS SUPPRELIN LA 58 Tumor Response 58 auristatin E MMAE 58 Archexin 58 overactive bladder AA# 58 Reports Preclinical Data 58 Multiple Ascending Dose 58 TNFerade TM 58 psoriasis rheumatoid arthritis 58 platinum refractory 58 pharmacodynamic profiles 58 Bosutinib 58 Sciences ABthrax Albuferon 58 PFE Short Term 58 FUSILEV enhances 58 First Patient Dosed 58 Pivotal Study 58 oral calcitonin licensed 58 PDE4 inhibitor 58 allosteric modulator PAM 58 Intermezzo ® zolpidem tartrate 58 Drug Shows Promise 58 Announce License Agreement 58 Hematide ™ 58 PINPOINT TM System 58 anti botulism antibody 58 Metastatic Colorectal Cancer 58 products MKC# PP 58 Methylnaltrexone 58 serum phosphorous 58 AKT inhibitor 58 please visit http:/www.vandapharma.com 58 cosmetic cosmeceutical products 58 tranquilizers diazepam 58 candidate REP# 58 Advanced Solid Tumors 58 HCV RNA polymerase 58 diarrhea predominant irritable 58 naïve HCV 58 HCl PEPCID ® famotidine 58 Phase Ib IIa 58 XL# XL# XL# XL# 58 including Mitochondrial Disorders 58 Ocrelizumab 58 ASG 5ME 58 treat chronic sinusitis 58 NicVAX TM 58 Eluting Stent 58 RCW breast cancer 58 ENABLE Phase 2 58 Nasdaq MNKD focused 58 orderonlineviagra 58 Nasdaq MNKD focuses 58 AVASTIN 58 Silodosin 58 oral anti arrhythmic 58 XL# XL# 58 initiated Phase Ib 58 Study Evaluating 58 ELADUR ™ 58 DNA methyltransferase inhibitors 58 zileuton injection 58 drug pipeline TAFA# 58 BUPHENYL R 58 pancreatic colon 58 dutogliptin 58 Therapeutic Competitors companiesandmarkets.com adEgemonye 58 recurrent glioblastoma multiforme 58 Heterozygous Familial Hypercholesterolemia 58 unresectable Stage III 58 Naive Patients 58 Inc. Nasdaq MITI 58 CCX# B 58 KRN# 58 class anticancer quinolone 58 investigational pharmacologically unique 58 Tibotec BVBA 58 omecamtiv mecarbil formerly 58 HCV NS5B polymerase 58 relapsed refractory multiple myeloma 58 IMA# 58 personalized cellular immunotherapy 58 GRNOPC1 contains 58 Vitamin D analogue 58 Phase 2b Trial 58 catheter occlusion 58 recurrent NSCLC 58 irinotecan containing 58 Squibb Genentech 58 PANVAC VF 58 ® chorionic gonadotropin 58 candidate ridaforolimus 58 Castration Resistant Prostate Cancer 58 Nanobody R 58 ALTROPANE R 58 SHP LN 58 PORxin TM platforms 58 hyperplasia BPH 58 Medoxomil 58 TRIOLEX ™ 58 includes TOLAMBA TM 58 2A receptor agonist 58 ELADUR TM 58 NS5b 58 Commence Phase 58 Genentech Boehringer Ingelheim 58 small molecule Hedgehog 58 Onalta 58 Pharmacokinetics PK 58 lead Aganocide compound 58 Plaque Psoriasis 58 MBRX 58 5 HT3 antagonist 58 Announces Poster Presentations 58 By JAMAAL ABDUL 58 HYVISC ® treatment 58 Pooled Analysis 58 ThermoDox ® clinical 58 Cephalon GlaxoSmithKline Organon 58 Limb Ischemia 58 Soft Tissue Sarcoma 58 balsalazide disodium Capsules 58 Biovest undertakes 58 rALLy clinical trial 58 http:/www.pharmion.com 58 Therapy RecoveryRx TM 58 GTC recombinant form 58 non resectable 58 NASH Huntington 57 RCW Breast Cancer 57 novel MetAP 2 57 NOTE POSIDUR ™ 57 RECORD1 57 steroid refractory GvHD 57 volociximab 57 developing Surfactant Replacement 57 Randomized Double Blind 57 infectious diseases autoimmune 57 using VIAdel TM 57 Forodesine HCl 57 oral dual endothelin 57 MKC# MKC# PP 57 Inc. ProMetic www.prometic.com 57 osteolytic bone disease 57 investigational mTOR inhibitor 57 controlled multicenter Phase 57 Pivotal Trial 57 Diovan Exforge Tekturna Zelnorm 57 potent CYP#A# inhibitors 57 commercializing oxidized glutathione 57 Entereg R 57 drugs FUSILEV 57 Dose Ranging 57 pediatric Crohn disease 57 delivery polymer matrix 57 undergoing elective percutaneous 57 either acutely decompensated 57 motexafin gadolinium Injection 57 Advanced Renal Cell 57 IAP inhibitor 57 Evoltra ® 57 adjuvant GIST 57 BRIM3 57 BioGlue R 57 Recurrent Breast Cancer 57 fungal infections malaria tuberculosis 57 Phase III Clinical Trial 57 NDA Submission 57 MSBlast exploits flaw 57 treatment naive genotype 57 Warner Chilcott Actonel 57 ferric citrate 57 4 PDE4 enzyme 57 NYSE PFE Exelon Rivastigmine 57 SUPPRELIN R LA 57 bleu cheese fritters 57 elderly myelodysplastic syndromes 57 Desvenlafaxine Succinate 57 pouvoir assassin 57 Kosan dependence 57 sitagliptin metformin 57 CE marked PROGENSA 57 interferon alpha IFN 57 APPRAISE 57 HuCAL PLATINUM ® CysDisplay 57 Potassium Chloride Sodium Ascorbate 57 Veronate R 57 recurrent malignant glioma 57 Novel Inhibitor 57 Completes Dosing 57 Ecallantide 57 Demonstrates Sustained 57 advanced carcinoid 57 Oral Suspension USP 57 non resectable metastatic 57 subtype selective NMDA receptor 57 huN# DM1 57 prokinetic agent 57 Relapsed Refractory 57 prostate cancer HRPC 57 Cadila Pharmaceuticals named 57 RapMAT R 57 accessories autologous 57 adenosine A2A 57 budesonide foam 57 Study Shows Promise 57 urinary bladder wall 57 included exfoliative dermatitis 57 CoTherix logo 57 ACTEMRA TM 57 Tanespimycin 57 following fluoropyrimidine oxaliplatin 57 STRIDE PD 57 Inc. NASDAQ QLTI 57 Iluvien ® 57 Primary Hypercholesterolemia 57 develop HBV reactivation 57 Fibrillex TM 57 5 lipoxygenase activating 57 relapsed Acute Myeloid 57 CRMD# 57 Shows Promise Against 57 faropenem medoxomil 57 GVAX R 57 oral proteasome inhibitor 57 non thiazolidinedione TZD 57 worsening thrombocytopenia 57 delta opioid receptor 57 R vitespen 57 alfimeprase direct 57 refractory NSCLC 57 USP Tablets PEPCID 57 DURECT proprietary 57 PDGFR B 57 Demonstrates Efficacy 57 RESTORE CLI trial 57 herpetic keratitis 57 Preclinical Study 57 plus gemcitabine 57 small molecule thrombopoietin 57 limiting toxicity DLT 57 migraine headaches neuropathic pain 57 cardiometabolic diseases Glucophage 57 treatment naïve genotype 57 J Am Acad 57 plus Copegus R 57 Statin medicines sold 57 synthetic ligand affinity 57 Lenocta TM 57 intranasal formulation 57 PROACT Phase 2 57 Phase Ib clinical trials 57 Confirmatory Phase 57 Unstable Angina 57 HCV protease inhibitor 57 Solazed 57 Chronic Lymphocytic Leukemia 57 TRANSDUR ™ 57 clinical trials Archexin 57 2hours #mins #.#secs M 57 signal detection CTSD 57 Proc Am Soc 57 R bendamustine hydrochloride 57 including thyroiditis RA 57 CML CP 57 HCV SPRINT 57 VIVITROL ® 57 SPEAR Study 57 MT# MEDI 57 Locteron combines 56 Intravenous Human 56 Ovarian Cancers 56 NASDAQ ALNY 56 Receives Tentative Approval 56 AVN# Phase 56 technology visit http:/www.genmab.com 56 Agonist MABA program 56 atypical Hemolytic Uremic Syndrome 56 Phase Ib II 56 BRIM2 56 read Palintologist 56 overactive bladder VANTAS R 56 damage cirrhosis liver 56 dem Ziel der europaweiten 56 Curis collaborator Genentech 56 Mentalist Ulrich 56 Novartis Organon 56 Agensys subsidiary 56 antibody MAb 56 SUCCEED trial 56 Taiho Pharmaceutical 56 evaluating pirfenidone 56 visit www.genenews.com 56 Initiated Phase 56 HuMax TAC 56 CAPACITY trials 56 ongoing Phase 1b 56 recurrent metastatic 56 gastrointestinal stromal tumor GIST 56 tumor lysis syndrome 56 Completes Patient Enrolment 56 Advancing Drugs 56 Cancer Incidence Mortality 56 proprietary radiolabeled monoclonal 56 dose escalation clinical 56 metastatic HRPC 56 oral rivaroxaban 56 Horizant ™ 56 refractory multiple myeloma 56 phase IIb clinical 56 induced macular edema 56 ELACYT 56 intravenous belinostat 56 RNAi Therapeutic 56 Aurora Kinase 56 Luramist TM 56 Phase 2a Clinical Trial 56 FSBO #/#/# Wood 56 cheap cialis paypal 56 retinal vein occlusion induced 56 Nasdaq VNDA 56 refractory cutaneous T 56 BENLYSTA belimumab 56 XL# XL# XL# 56 Pivotal Clinical Trial 56 Adenoscan R 56 By JENNIFER LEARN 56 administering VIVITROL 56 INVESTING IN SECURITIES INVOLVES 56 Occlusive Disease 56 International LAB Pharma 56 Treatment Shows Promise 56 refractory metastatic colorectal cancer 56 See CLINICAL PHARMACOLOGY 56 By QianMian #-#-# 56 Hemispherx flagship products 56 anthracycline derivative 56 website www.celsion.com 56 XIAFLEX ® 56 Glatiramer Acetate 56 product platforms AZX# 56 ZACTIMA 56 polysaccharide polymer 56 Platinol ® 56 Elestrin ® 56 Predict Response 56 CD4 monoclonal antibody 56 acute mania 56 PEGINTRON REBETOL combination 56 failure thrombosis embolism 56 candidate SILENOR TM 56 Frozen Shoulder syndrome Adhesive 56 cutaneous T 56 evaluating Prochymal 56 HRPC ovarian cancer 56 Hodgkin lymphoma HL 56 Prospective Randomized 56 OTCBB URGP specialty 56 Clinical Trial Evaluating 56 Phase 2b Study 56 Allovectin 7 56 markets XIFAXAN ® 56 synthetic lipoglycopeptide antibiotic 56 Shows Promising 56 DARA logo 56 oligonucleotides Manoharan 56 Nasdaq IMGN 56 Advanced CustomVue Wavefront 56 severe oral mucositis 56 MT#/MEDI-# 56 Relapsed 56 Unit Dose Budesonide 56 Synta Announces 56 pseudobulbar affect PBA 56 Nicotine Conjugate Vaccine 56 gets USFDA nod 56 Pathway Inhibitor 56 generation nucleoside analog 56 ZALBIN 56 Picoplatin Efficacy After 56 fallopian tube cancers 56 Medisorb ® 56 Phase III Pivotal 56 MULLIGAN FAMILY FUN CENTER 56 provides adenoviral reagents 56 DP VPA 56 Nasdaq HNAB 56 unresectable locally advanced 56 proprietary intranasal insulin 56 cathepsin K inhibitor